Imara to Present at Upcoming Investor Conferences

Rhea-AI Summary

BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA) announced its participation in key virtual investor conferences this September. CEO Rahul Ballal, Ph.D., will present at the Citi 15th Annual BioPharma Virtual Conference on September 9 and 10, discussing challenges in rare disease drug development and benign hematology. Additionally, he will engage in a virtual fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on September 17. Live webcasts will be available on Imara's website.

BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the Company will participate in the following upcoming virtual investor conferences in September:

• Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara will participate in two panel presentations at the Citi 15^th Annual BioPharma Virtual Conference:
  -  Wednesday, September 9, 2020 at 4:15 p.m. ET - Challenges and Opportunities in Rare Disease Drug Development
  -  Thursday, September 10, 2020 at 4:15 p.m. ET - Benign Hematology 

• Dr. Ballal will participate in a virtual fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on September 17, 2020 at 10:15 a.m. ET.

A live webcast of the presentations will be available under "Events and Presentations" in the Investors section of the company's website at www.imaratx.com.

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.

Media Contact:
Gina Nugent
Ten Bridge Communications
617-460-3579
gina@tenbridgecommunications.com

Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com

FAQ

What events is Imara participating in September 2020?

Imara will participate in the Citi 15th Annual BioPharma Virtual Conference on September 9 and 10, and the Morgan Stanley 18th Annual Global Healthcare Conference on September 17, 2020.

Who is presenting at the Citi conference for Imara?

Rahul Ballal, Ph.D., President and CEO of Imara, will present at the Citi conference.

What will Dr. Ballal discuss at the Citi conference?

Dr. Ballal will discuss challenges in rare disease drug development and benign hematology during the Citi conference.

When is the Morgan Stanley conference featuring Imara?

The Morgan Stanley 18th Annual Global Healthcare Conference featuring Imara is on September 17, 2020.

Where can I watch Imara's conference presentations?

The presentations will be available via live webcast under 'Events and Presentations' on Imara's website.